FDA Clearance Tracker · P910018-S037
LIPOSORBER(R) LA-15 SYSTEM ADSORPTION COLUMN, SULFUX(R) FS-05 PLASMA SEPARATOR, AND TUB. SYST. FOR PLASMAPHER. (LT-MA2).
Last checked: Nov 20, 2026Latest source record: Mar 5, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Mar 5, 2025
Approved
Time to decision
222 days
Received Jul 26, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P910018-S037
- Device name
- LIPOSORBER(R) LA-15 SYSTEM ADSORPTION COLUMN, SULFUX(R) FS-05 PLASMA SEPARATOR, AND TUB. SYST. FOR PLASMAPHER. (LT-MA2).
- Applicant
- Kaneka Pharma America Corp.
- Applicant location
- New York, NY
- Received
- Jul 26, 2024
- Decided
- Mar 5, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P910018
Device type
- Device type
- Lipoprotein, low density, removal (MMY)
- Device class
- Class III
- Specialty
- GI, Urology & Nephrology
FDA's approval statement
As written in FDA's record.
The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of the above referenced premarket approval application (PMA) 180-day supplement(s)/75-day humanitarian device exemption (HDE) supplement(s), which requested approval for packaging material (the shape of the cap, removing one material (styrene elastomer) from the cap, and the welding of the cap to the device), labeling, and a new sterilization site at Kaneka Corporation Tomatoh Plant Tomakomai, Hokkaido, 059-1362 Japan.
Source documents
Other decisions for Kaneka Pharma America Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.